Andexanet alpha-induced heparin resistance treated by nafamostat mesylate in a patient undergoing total aortic arch repair for Stanford type A acute aortic dissection: a case report
Abstract Background Andexanet alfa, an anti-Xa inhibitor antagonist, induces heparin resistance. Here, we report a case of successful management of cardiopulmonary bypass with andexanet alfa-induced heparin resistance using nafamostat mesylate. Case presentation An 84-year-old female, with Stanford...
Main Authors: | Yasuhito Suzuki, Mutsuhito Kikura, Shingo Kawashima, Tetsuro Kimura, Yoshiki Nakajima |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2024-01-01
|
Series: | JA Clinical Reports |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40981-024-00690-8 |
Similar Items
-
Successful use of an antithrombin for heparin resistance with andexanet alfa
by: Jun Honda, et al.
Published: (2023-05-01) -
Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
by: Weiwei Qian, et al.
Published: (2023-09-01) -
Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
by: Shinya Kameda, et al.
Published: (2023-01-01) -
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
by: Toru Hifumi, et al.
Published: (2020-08-01) -
Nafamostat Mesylate Improved Survival Outcomes of Sepsis Patients Who Underwent Blood Purification: A Nationwide Registry Study in Japan
by: Hiroshi Kamijo, et al.
Published: (2020-08-01)